ReNeuron Group plc (LON:RENE – Get Free Report)’s share price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 3.96 ($0.05) and traded as low as GBX 3.28 ($0.04). ReNeuron Group shares last traded at GBX 3.38 ($0.04), with a volume of 177,373 shares traded.
ReNeuron Group Stock Performance
The company’s 50 day simple moving average is GBX 3.38 and its 200 day simple moving average is GBX 3.96. The company has a debt-to-equity ratio of 14.25, a quick ratio of 2.02 and a current ratio of 1.51. The stock has a market cap of £1.93 million, a PE ratio of -37.50 and a beta of 0.69.
About ReNeuron Group
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease.
Recommended Stories
- Five stocks we like better than ReNeuron Group
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- How to Buy the Dip and Sell the Rip on Your Stocks with Options
- Basic Materials Stocks Investing
- 3 Hot Buyback Plans Supporting Price Action in 2024
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Stocks With Subscription Based Revenue Offer Inflation Protection
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.
